Massachusetts 191st Legislature (2019-2020) Status: In Committee

S 696 — An Act to promote transparency and cost control of pharmaceutical drug prices

Last action — Ought NOT to pass (under Joint Rule 10) and placed in the Orders of the Day for the next session

  1. ✓
    Introduced
  2. 2
    In Committee
  3. 3
    Passed Senate
  4. 4
    Passed House
  5. 5
    To Executive
  6. 6
    Enacted

This bill died with 191st Legislature (2019-2020). It reached “In Committee” and never advanced before the session ended, so it can no longer move — a new version would have to be reintroduced in the current session.

This bill is no longer active — its legislative session has ended, so there is no live prognosis. It would have to be reintroduced in the current session to move again.

Summary

By Mr. Lesser, a petition (accompanied by bill, Senate, No. 696) of Eric P. Lesser, Diana DiZoglio and José F. Tosado for legislation to promote transparency and cost control of pharmaceutical drug prices. Health Care Financing.

Bill Text

We don't have the full text on file for this bill yet.

Read S 696 on the official Massachusetts source →

Action History

  1. Ought NOT to pass (under Joint Rule 10) and placed in the Orders of the Day for the next session

  2. Reporting date extended to Thursday December 31, 2020, pending concurrence

  3. Senate concurred

  4. Reporting date extended to Friday June 19, 2020, pending concurrence

  5. Senate concurred

  6. Reporting date extended to Friday May 1, 2020, pending concurrence

  7. Hearing scheduled for 04/11/2019 from 01:00 PM-04:00 PM in A-1

  8. House concurred

  9. Referred to the committee on Health Care Financing

Sponsors

  • Eric P. Lesser · Primary
  • Eric P. Lesser · Cosponsor
  • Diana DiZoglio · Cosponsor
  • José F. Tosado · Cosponsor

Sponsorship breakdown

Export CSV (upgrade) →

1 sponsors · 3 co-sponsors · 200 not signed on

Sponsors (1)

  • Eric P. Lesser

Co-sponsors (3)

  • Eric P. Lesser
  • Diana DiZoglio
  • José F. Tosado

Not signed on (200)

200 members have not signed on to this bill.

Show all 200 →

"Not signed on" means a member has not sponsored or co-sponsored this bill — it does not imply opposition. Members flagged Voted No have a recorded No vote on this bill.

Whip count is in markup. Polling the chamber and every recorded vote this session. Only the first open is slow. It’s instant for you after this. Calling the roll · Tallying · Engrossing

Subjects

healthcare health-insurance
Cross-referencing the record. Reading this bill against every other bill in the corpus by meaning, not keywords. Only the first open is slow. It’s instant for you after this. Matching · Ranking · Engrossing

Frequently asked questions

What does S 696 do?
By Mr. Lesser, a petition (accompanied by bill, Senate, No. 696) of Eric P. Lesser, Diana DiZoglio and José F. Tosado for legislation to promote transparency and cost control of pharmaceutical drug prices. Health Care Financing.
Who sponsors S 696?
S 696 is sponsored by Eric P. Lesser, Diana DiZoglio, and José F. Tosado.
What is the current status of S 696?
This bill died with 191st Legislature (2019-2020). It reached “In Committee” and never advanced before the session ended, so it can no longer move — a new version would have to be reintroduced in the current session.
Where can I track S 696?
Track S 696 free on One Click Politics — get push/email alerts when it moves.

Make your voice heard on S 696

Find the representatives who decide this bill and tell them where you stand — for yourself, or mobilize your whole list in one click with One Click Politics advocacy software.

Find my representatives → Run a campaign

Stay ahead of S 696

Last checked for changes 3 months ago · updated continuously

One Click Politics tracks every bill in Congress and all 50 states.

Track this bill →